Positron Emission Tomography (PET) News and Research

RSS

Physiological processes in soft tissue pain explored using PET imaging

Physiological processes in soft tissue pain such as chronic tennis elbow can be explored using diagnostic imaging methods. This is demonstrated by researchers from Uppsala University and the results are now being published in the prestigious journal PLOS ONE.

29 Oct 2013

Zecotek showcases patented imaging technologies at Nuclear Science Symposium

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company will be attending the Nuclear Science Symposium and Medical Imaging Conference in Seoul Korea from October 27 through November 2, 2013 in Seoul, Korea.

28 Oct 2013

Researchers discover potential method to identify TBI using positron PET scans

Accurately diagnosing traumatic brain injuries (TBI) and concussions is difficult, as standard CT or MRI scans can't see most changes to the brain caused by these injuries.

24 Oct 2013

PET scan shows promise in predicting patients with inoperable lung cancer

Advanced imaging with Positron Emission Tomography (PET) scan shows great promise in predicting which patients with inoperable lung cancer have more aggressive tumors and need additional treatment following standard chemotherapy/radiation therapy, according to new research recently published online in the Journal of Clinical Oncology.

8 Oct 2013

High-dose statins could have added benefit of reducing gum inflammation

The use of high-dose statins to lower cholesterol in heart disease patients appears to have the added benefit of reducing gum inflammation, according to research published in the Journal of the American College of Cardiology.

4 Oct 2013

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

...

24 Sep 2013

First Direct Measurement Of Spinal Cord Myelin In MS

...

24 Sep 2013

Researchers develop first imaging tool to examine myelin damage in MS

Researchers have made an exciting breakthrough - developing a first-of-its-kind imaging tool to examine myelin damage in multiple sclerosis (MS). An extremely difficult disease to diagnose, the tool will help physicians diagnose patients earlier, monitor the disease's progression, and evaluate therapy efficacy.

24 Sep 2013

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

At the 2013 World Molecular Imaging Congress (WMIC, www.wmicmeeting.org), Bruker today announced the world’s first Magnetic Particle Imaging (MPI) system, an entirely new technology for preclinical imaging. The addition of MPI as a complementary preclinical imaging technique for disease studies, translational research and drug discovery, has significant potential in helping researchers gain new insights into disease processes at the organ, cellular and molecular level.

From Bruker BioSpin - NMR, EPR and Imaging 19 Sep 2013

Multimodal animal bed introduced by Bruker

Today, at the 2013 World Molecular Imaging Congress (WMIC), Bruker introduces a new multimodal animal bed enabling multiple sequential imaging sessions in preclinical research with robust repositioning between scans, while avoiding unwanted motion of the animal during the investigation. This optimizes results for image fusion, combined processing and evaluation of preclinical research applications requiring multiple imaging modalities across multiple systems.

From Bruker BioSpin - NMR, EPR and Imaging 19 Sep 2013

NIEHS grant renewal opens next chapter in 18-year research effort into brain injury biomarker

The National Institute of Environmental Health Sciences (NIEHS) has awarded a five-year, $1.5 million grant extension to Columbia University's Mailman School of Public Health to fund research into the function of a biomarker for brain injury called Translocator Protein 18 kDa, better known as TSPO, in order to better understand its function in brain injury and inflammation and discover targets for therapy.

17 Sep 2013

Omeros announces positive data from OMS824 Phase 1 clinical trial

Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.

12 Sep 2013

PET imaging predicts favorable outcome after decompressive surgery in patients with cervical myelopathy

For patients with degenerative cervical myelopathy, imaging with 18F-FDG positron emission tomography (PET) could act as a marker for a potentially reversible phase of the disease in which substantial clinical improvement can be achieved.

5 Sep 2013

Patient-relevant benefit of PET or PET/CT in oesophageal cancer is still unclear

The patient-relevant benefit of positron emission tomography (PET) in oesophageal cancer, alone or in combination with computed tomography (CT), is not proven due to a lack of comparative studies. In terms of their diagnostic and prognostic accuracy, it also remains unclear whether these diagnostic techniques can detect the spreading of tumours better than conventional diagnostics.

29 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Dopamine responses to alcohol ingestion may serve as marker of vulnerability to AUDs

There are two traits closely associated with the development of alcohol use disorders (AUDs). One is a lower subjective intoxication response, also known as a low level of response to alcohol.

12 Aug 2013

Alcohol use increases risk of dopamine response in brain pathway

Research from McGill University suggests that people who are vulnerable to developing alcoholism exhibit a distinctive brain response when drinking alcohol, according to a new study by Prof. Marco Leyton, of McGill University's Department of Psychiatry.

3 Aug 2013

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has received a $500,000 order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from its strategic partner Hamamatsu Photonics (Tokyo: 6965) of Japan.

31 Jul 2013

Results of post-mortem brain tissue study using Navidea's NAV4694 imaging agent presented at AAIC 2013

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.

23 Jul 2013

Long-term cannabis use, dopamine and motivation: an interview with Dr Michael Bloomfield, Department of Medicine at Imperial

We classified ‘long-term’ cannabis use as being regular, at least weekly, cannabis use for over 12 months. This is the period of time that’s used in the DSM-IV psychiatric diagnostic manual to classify substance use disorders. In our study the average duration of at least weekly use was just over four and a half years.

17 Jul 2013

Positron Emission Tomography (PET) News and Research

Physiological processes in soft tissue pain explored using PET imaging

Zecotek showcases patented imaging technologies at Nuclear Science Symposium

Researchers discover potential method to identify TBI using positron PET scans

PET scan shows promise in predicting patients with inoperable lung cancer

High-dose statins could have added benefit of reducing gum inflammation

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

First Direct Measurement Of Spinal Cord Myelin In MS

Researchers develop first imaging tool to examine myelin damage in MS

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

Multimodal animal bed introduced by Bruker

NIEHS grant renewal opens next chapter in 18-year research effort into brain injury biomarker

Omeros announces positive data from OMS824 Phase 1 clinical trial

PET imaging predicts favorable outcome after decompressive surgery in patients with cervical myelopathy

Patient-relevant benefit of PET or PET/CT in oesophageal cancer is still unclear

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Dopamine responses to alcohol ingestion may serve as marker of vulnerability to AUDs

Alcohol use increases risk of dopamine response in brain pathway

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Results of post-mortem brain tissue study using Navidea's NAV4694 imaging agent presented at AAIC 2013

Long-term cannabis use, dopamine and motivation: an interview with Dr Michael Bloomfield, Department of Medicine at Imperial

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News